Cognitive impairment in diabetes mellitus and hypertension, a possibility of correction

Objective: to evaluate cognitive functions in patients with type 2 diabetes mellitus (DM2) and hypertension and the efficacy of Ginkgo biloba extract Egb 761®.

Patients and methods. 120 patients with DM2 and 50 hypertensive patients with no complications or a history of stroke and/or myocardial infarction, without active complaints of hypomnesia and other cognitive functions were examined. The exclusion criteria were prior stroke and/or myocardial infarction; clinically significant diseases of the peripheral arteries and major arteries of the head; DM2 decompensation; glomerular filtration rate <60 ml/min; proliferative retinopathy; and other endocrine diseases. The investigators used the following methods for the evaluation of cognitive functions: the Mini-Mental State Examination, the Montreal Cognitive Assessment, and the hand- eye coordination test (Parts A and B).

Results and discussion. 85% of the patients with DM2 were found to have cognitive impairments (CI): disorders of attention, short-term memory, and thinking speed. Out of them, 82.5% had moderate CI and 2.5% had dementia. 30% of the hypertensive patients were diagnosed as having moderate CIs and 10% had dementia. At the same time, the degree of CI was higher in the patients with MD2 than in those with hypertension. The use of Egb 761® 240 mg/day for 3 months had a statistically significant positive impact on cognitive functions (improvements in short-term memory, concentration, and thinking speed) and everyday activity.

Conclusion. The authors consider that CIs are the first sign of encephalopathy in DM2. It is also noted that DM2 has a more pronounced impact on cognitive functions than hypertension. Egb 761® can be used as an effective drug to treat CI in these diseases.

1. Дамулин ИВ. Сосудистая деменция: патогенез, диагностика и лечение. Фарматека. 2010;(7):13-8. [Damulin IV. Vascular dementia: pathogenesis, diagnosis and treatment. Farmateka. 2010;(7):13-8. (In Russ.)].

2. Парфенов ВА. Дифференциальный диагноз и лечение дисциркуляторной энцефалопатии. Consilium-medicum. 2013;(9):28-32. [Parfenov VA. Differential diagnosis and treatment of dyscirculatory encephalopathy. Consilium-medicum. 2013;(9):28-32. (In Russ.)].

3. O'Brien J, Erkinjuntti T, Reisberg T, et al. Vascular cognitive impairment. The Lancet Neurology. 2003;2(2):89-98. doi:10.1016/s1474-4422(03)00305-3.

4. Есин РГ, Хайруллин ИХ, Есин ОР и др. Диабетическая энцефалопатия: патогенез, клинические проявления, подходы к терапии. Клиницист. 2012;(3):10-6. [Esin RG, Khairullin IKh, Esin OR, et al. Diabetic encephalopathy: pathogenesis, clinical manifestations, approaches to therapy. Klinitsist. 2012;(3):10-6. (In Russ.)]. doi:10.17650/1818-8338-2012-3-4-10-16

5. Хуторная ОЕ, Бреговский ВБ, Демина АГ, Карпова ИА. Гетерогенность болевой диабетической полинейропатии и дифференцированный подход к ее лечению. Сахарный диабет. 2013;(2):62-6. [Khutornaya OE, Bregovskii VB, Demina AG, Karpova IA. Heterogeneity of painful diabetic neuropathy and differential approach to its treatment. Sakharnyi diabet. 2013;(2):62-6. (In Russ.)]. doi:10.14341/2072-0351-3757

6. Dyck P, Albers J, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes/Metabolism Research and Reviews. 2011;27(7):620-8. doi:10.1002/dmrr.1226.

7. Miles W, Root H. Psychologic tests applied in diabetic patients. Arch Intern Med. 1922; (30): 767-70.

8. Строков ИА, Захаров ВВ, Строков КИ. Диабетическая энцефалопатия. Неврология, нейропсихиатрия, психосоматика. 2012;4(2S):30-40. [Strokov IA, Zakharov VV, Strokov KI. Diabetic encephalopathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2S):30-40. (In Russ.)]. doi:10.14412/ 2074-2711- 2012-2506

9. Товажнянская ЕЛ, Безуглова ИО, Наврузов МБ, Балковая НС. Умеренные когнитивные нарушения при сахарном диабете 2- го типа. Международный медицинский журнал. 2012;(1):6-9. [Tovazhnyanskaya EL, Bezuglova IO, Navruzov MB, Balkovaya NS. Mild cognitive impairment in diabetes of the 2nd type. Mezhdunarodnyi meditsinskii zhurnal. 2012;(1):6-9. (In Russ.)].

10. Myint A. Alzheimer’s Disease and Type 2 Diabetes mellitus: risk factors and effectiveness of antidiabetic agents in treatment of Alzheimer’s disease. SJCM. 2013;2(3):114. doi:10.11648/j.sjcm. 20130203.20.

11. Umegaki H. Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin Interv Aging. 2014 Jun 28;9:1011-9. doi: 10.2147/CIA.S48926. eCollection 2014.

12. Vijayakumar T, Sirisha G, Farzana B, Dhanaraju M. Mechanism linking cognitive impairment and diabetes mellitus. European Journal of Applied Sciences. 2012;4(1):1-5.

13. Хайруллин ИХ, Есин РГ, Поздняк АО. Возможности коррекции когнитивного снижения у пациентов с сахарным диабетом 2 типа. Журнал неврологии и психиатрии им. С.С.Корсакова. 2014;(9):19-23. [Khairullin IKh, Esin RG, Pozdnyak AO. Possibilities of correction of cognitive impairment in patients with diabetes mellitus type 2. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2014;(9):19-23. (In Russ.)].

14. Folstein M, Folstein S, McHugh P. «Mini-Mental State»: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.

15. MoCA version august 18, 2010© Nasreddine Z. www.mocatest.org 16. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002 Mar;8(3):448-60. doi:10.1017/s1355617702813248.

16. Corrigan J, Hinkeldey M. Relationships between parts A and B of the Trail Making Test. J Clin Psychol. 1987 Jul;43(4):402-9.

17. Хафизьянова РХ, Бурыкин ИМ, Алеева ГН. Математическая статистика в экспериментальной и клинической фармакологии: монография. Казань: Медицина; 2006. [Khafiz'yanova RKh, Burykin IM, Aleeva GN. Matematicheskaya statistika v eksperimental'noi i klinicheskoi farmakologii: monografiya [Mathematical statistics in experimental and clinical pharmacology: monograph]. Kazan': Meditsina; 2006.]

18. Реброва ОЮ. Статистический анализ медицинских данных. Применение пакета прикладных программ Statistica. Москва: Медиа Сфера; 2002. [Rebrova OYu. Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm Statistica [Statistical analysis of medical data. Application of software package Statistica]. Moscow: Media Sfera; 2002.]

19. Кадыков АС, Шахпаровнова НВ, Кадыков АВ. Гипертоническая энцефалопатия: узловые точки диагностики и лечения. Consilium medicum. 2013;(2):36-9. [Kadykov AS, Shakhparovnova NV, Kadykov AV. Hypertensive encephalopathy: the key points of diagnosis and treatment. Consilium medicum. 2013;(2):36-9. (In Russ.)].

20. Wysocki M, Luo X, Schmeidler J, et al. Hypertension is Associated With Cognitive Decline in Elderly People at High Risk for Dementia. Am J Geriatr Psychiatry. 2012 Feb;20(2):179-87. doi: 10.1097/JGP.0b013e31820ee833.

21. Goldstein F, Levey A, Steenland N. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc. 2013 Jan;61(1):67-73. doi: 10.1111/jgs.12067. Epub 2013 Jan 10.

22. Наприенко МВ, Есин РГ, Мухаметова ЭР и др. Танакан — мультимодальный цитопротектор для общемедицинской практики (часть 1). Журнал неврологии и психиатрии им. С.С.Корсакова. 2015;(11):146-51. [Naprienko MV, Esin RG, Mukhametova ER, et al. Tanakan – multimodal cytoprotector for General medical practice (part 1). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2015;(11):146-51. (In Russ.)]. doi: 10.17116/jnevro2015115111146-151

23. Есин РГ, Наприенко МВ, Мухаметова ЭР и др. Танакан – мультимодальный цитопротектор для общемедицинской практики (часть 2). Журнал неврологии и психиатрии им. С.С.Корсакова. 2015;(12):157-62. [Esin RG, Naprienko MV, Mukhametova ER i dr. Tanakan – multimodal cytoprotector for General medical practice (part 2). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2015;(12):157-62. (In Russ.)]. doi:10.17116/jnevro2015115112177-182